Modification of Drug Response in Cancer by MicroRNAs

Laura L. Meijer, Jisce R. Puik, Caterina Vivaldi, Mjriam Capula, Enrico Vasile, Geert Kazemier, Elisa Giovannetti

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Especially in chemoresistant cancers, such as lung and pancreatic cancer, there is a clear need to understand molecular mechanisms behind drug resistance and develop effective therapies. Resistance can be caused by a range of mechanisms, including modulation by microRNAs (miRNAs). miRNAs are involved in many biological processes and have been implicated in cancer initiation and progression. However, they can also alter cellular response to anticancer agents by modulating survival pathways, apoptosis and DNA repair systems. One of the major features of miRNAs is their ability to target multiple genes and therefore interfere in multiple pathways. This explains their role in multiple pathways involved in resistance and makes them attractive as novel class of therapeutic targets. Here, we describe the molecular basis of miRNAs in anticancer drug resistance, including alterations in cell survival and apoptosis, as well as drug targets. The possibility to modulate miRNA expression to enhance drug sensitivity and the development of miRNA-based therapeutics as novel drugs is discussed. The implications are illustrated with a clinical focus on the application of miRNAs in pancreatic cancer and lung cancer, for which resistance to current therapies remains a major problem.
Original languageEnglish
Title of host publicationRSC Drug Discovery Series
PublisherRoyal Society of Chemistry
Pages416-451
Volume2019-January
DOIs
Publication statusPublished - 2019

Publication series

NameRSC Drug Discovery Series
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Cite this

Meijer, L. L., Puik, J. R., Vivaldi, C., Capula, M., Vasile, E., Kazemier, G., & Giovannetti, E. (2019). Modification of Drug Response in Cancer by MicroRNAs. In RSC Drug Discovery Series (Vol. 2019-January, pp. 416-451). (RSC Drug Discovery Series). Royal Society of Chemistry. https://doi.org/10.1039/9781788016421-00416
Meijer, Laura L. ; Puik, Jisce R. ; Vivaldi, Caterina ; Capula, Mjriam ; Vasile, Enrico ; Kazemier, Geert ; Giovannetti, Elisa. / Modification of Drug Response in Cancer by MicroRNAs. RSC Drug Discovery Series. Vol. 2019-January Royal Society of Chemistry, 2019. pp. 416-451 (RSC Drug Discovery Series).
@inbook{85d674e960b643fc88a2140e78026d6f,
title = "Modification of Drug Response in Cancer by MicroRNAs",
abstract = "Especially in chemoresistant cancers, such as lung and pancreatic cancer, there is a clear need to understand molecular mechanisms behind drug resistance and develop effective therapies. Resistance can be caused by a range of mechanisms, including modulation by microRNAs (miRNAs). miRNAs are involved in many biological processes and have been implicated in cancer initiation and progression. However, they can also alter cellular response to anticancer agents by modulating survival pathways, apoptosis and DNA repair systems. One of the major features of miRNAs is their ability to target multiple genes and therefore interfere in multiple pathways. This explains their role in multiple pathways involved in resistance and makes them attractive as novel class of therapeutic targets. Here, we describe the molecular basis of miRNAs in anticancer drug resistance, including alterations in cell survival and apoptosis, as well as drug targets. The possibility to modulate miRNA expression to enhance drug sensitivity and the development of miRNA-based therapeutics as novel drugs is discussed. The implications are illustrated with a clinical focus on the application of miRNAs in pancreatic cancer and lung cancer, for which resistance to current therapies remains a major problem.",
author = "Meijer, {Laura L.} and Puik, {Jisce R.} and Caterina Vivaldi and Mjriam Capula and Enrico Vasile and Geert Kazemier and Elisa Giovannetti",
year = "2019",
doi = "10.1039/9781788016421-00416",
language = "English",
volume = "2019-January",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
pages = "416--451",
booktitle = "RSC Drug Discovery Series",
address = "United Kingdom",

}

Meijer, LL, Puik, JR, Vivaldi, C, Capula, M, Vasile, E, Kazemier, G & Giovannetti, E 2019, Modification of Drug Response in Cancer by MicroRNAs. in RSC Drug Discovery Series. vol. 2019-January, RSC Drug Discovery Series, Royal Society of Chemistry, pp. 416-451. https://doi.org/10.1039/9781788016421-00416

Modification of Drug Response in Cancer by MicroRNAs. / Meijer, Laura L.; Puik, Jisce R.; Vivaldi, Caterina; Capula, Mjriam; Vasile, Enrico; Kazemier, Geert; Giovannetti, Elisa.

RSC Drug Discovery Series. Vol. 2019-January Royal Society of Chemistry, 2019. p. 416-451 (RSC Drug Discovery Series).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

TY - CHAP

T1 - Modification of Drug Response in Cancer by MicroRNAs

AU - Meijer, Laura L.

AU - Puik, Jisce R.

AU - Vivaldi, Caterina

AU - Capula, Mjriam

AU - Vasile, Enrico

AU - Kazemier, Geert

AU - Giovannetti, Elisa

PY - 2019

Y1 - 2019

N2 - Especially in chemoresistant cancers, such as lung and pancreatic cancer, there is a clear need to understand molecular mechanisms behind drug resistance and develop effective therapies. Resistance can be caused by a range of mechanisms, including modulation by microRNAs (miRNAs). miRNAs are involved in many biological processes and have been implicated in cancer initiation and progression. However, they can also alter cellular response to anticancer agents by modulating survival pathways, apoptosis and DNA repair systems. One of the major features of miRNAs is their ability to target multiple genes and therefore interfere in multiple pathways. This explains their role in multiple pathways involved in resistance and makes them attractive as novel class of therapeutic targets. Here, we describe the molecular basis of miRNAs in anticancer drug resistance, including alterations in cell survival and apoptosis, as well as drug targets. The possibility to modulate miRNA expression to enhance drug sensitivity and the development of miRNA-based therapeutics as novel drugs is discussed. The implications are illustrated with a clinical focus on the application of miRNAs in pancreatic cancer and lung cancer, for which resistance to current therapies remains a major problem.

AB - Especially in chemoresistant cancers, such as lung and pancreatic cancer, there is a clear need to understand molecular mechanisms behind drug resistance and develop effective therapies. Resistance can be caused by a range of mechanisms, including modulation by microRNAs (miRNAs). miRNAs are involved in many biological processes and have been implicated in cancer initiation and progression. However, they can also alter cellular response to anticancer agents by modulating survival pathways, apoptosis and DNA repair systems. One of the major features of miRNAs is their ability to target multiple genes and therefore interfere in multiple pathways. This explains their role in multiple pathways involved in resistance and makes them attractive as novel class of therapeutic targets. Here, we describe the molecular basis of miRNAs in anticancer drug resistance, including alterations in cell survival and apoptosis, as well as drug targets. The possibility to modulate miRNA expression to enhance drug sensitivity and the development of miRNA-based therapeutics as novel drugs is discussed. The implications are illustrated with a clinical focus on the application of miRNAs in pancreatic cancer and lung cancer, for which resistance to current therapies remains a major problem.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067365135&origin=inward

U2 - 10.1039/9781788016421-00416

DO - 10.1039/9781788016421-00416

M3 - Chapter

VL - 2019-January

T3 - RSC Drug Discovery Series

SP - 416

EP - 451

BT - RSC Drug Discovery Series

PB - Royal Society of Chemistry

ER -

Meijer LL, Puik JR, Vivaldi C, Capula M, Vasile E, Kazemier G et al. Modification of Drug Response in Cancer by MicroRNAs. In RSC Drug Discovery Series. Vol. 2019-January. Royal Society of Chemistry. 2019. p. 416-451. (RSC Drug Discovery Series). https://doi.org/10.1039/9781788016421-00416